Uric acid: Bystander or culprit in hypertension and progressive renal disease

Journal of Hypertension

Volumn 26, Issue 11, 2008, Pages 2085-2092

  Menè, Paolo ^a   Punzo, Giorgio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Arterial hypertension; Fructose; Lactate; Urate nephropathy; Urateoxidase; Uric acid

Indexed keywords

ALLOPURINOL; BENZIODARONE; CYCLOSPORIN A; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FEBUXOSTAT; FRUCTOSE; LOOP DIURETIC AGENT; OXONIC ACID; THIAZIDE DIURETIC AGENT; URIC ACID;

ALBUMINURIA; BLOOD VOLUME; BYSTANDER EFFECT; CELL PROLIFERATION; CLINICAL TRIAL; ENZYME INHIBITION; GLOMERULOSCLEROSIS; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; INSULIN RESISTANCE; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE ABSORPTION; METABOLIC SYNDROME X; MICROANGIOPATHY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; PURINE METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URIC ACID NEPHROPATHY; VASCULAR SMOOTH MUSCLE; ANIMAL; DISEASE MODEL; KIDNEY DISEASE; METABOLISM; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASES; RATS; URIC ACID;

EID: 56049126638     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32830e4945     Document Type: Review

References (91)

1. Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG. Uric acid transport. hCurr Opin Nephrol Hypertens 20032:511-516.
2. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33:225-234.
3. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40:355-360.
4. Johnson RJ, Segal MS, Srinivas T, Ejaz A, MuW, Roncal C, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link J Am Soc Nephrol 2005; 16:1909-1919.
5. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology (Bethesda) 2005; 20:125-133.
6. Arrambide K, Toto RD.Tumor lysis syndrome. Semin Nephrol 1993;13:273-280.
7. CairoMS, BishopM. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127:3-11.
8. Wilcox WR, Khalaf A, Weinberger A, Kippen I, Klinenberg JR. Solubility of uric acid and monosodium urate. Mol Biol Engl 1972; 10:522-531.
9. Peronato G. Purine metabolism and hyperuricemic states. Contrib Nephrol 1995; 147:1-21.
10. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease:molecular mechanisms and pathophysiological implications. J Physiol 2004; 555:589-606.
11. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998; 31:27-28.
12. Simmonds HA, Sabota AS, Van Acker KJ. Adenine phosphoribosyltransferase deficiency and 2,8-dihydroxyadenine lithiasis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basisof inherited disease, 6th ed. New York: McGraw-Hill; 1989. pp. 1029-1044.
13. Edvardsson V, Palsson R, Olafsson I, Hjaltadottir G, Laxdal T. Clinical features and genotype of adenine phosphoribosyltransferase deficiency inIceland. Am J Kidney Dis 2001; 38:473-480.
14. Imaoka T, Kusuhara H, Adachi-Akahane S, Hasegawa M, Morita N, Endou H, et al. The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. Jam Soc Nephrol 2004; 15:2012-2022.
15. Habu Y, Yano I, Okuda M, Fukatsu A, Inui K. Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney. Biochem Pharmacol 2005; 69:993-999.
16. Van Aubel RA, Smeets PH, van den Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an effiux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol (Renal Physiol) 2005; 288:F327-F333.
17. Faller J, Fox IH. Ethanol-induced hyperuricemia. Evidence for increased urate production by activation of adenine nucleotide turnover. N Engl JMed 1982; 307:1598-1602.
18. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal- independent mechanism. Hypertension 2001; 38:1101-1106.
19. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol (Renal Physiol) 2002; 282:F991-F997.
20. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats.Kidney Int 2005; 67:237-247.
21. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45:18-20.
22. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease Hypertension 2003; 41:1183-1190.
23. Khan HA, Medalie JH, Neufeld HN, Riss E, Goldbourt U. The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J 1972; 84:171-182.
24. Selby JV, Friedman GD, Quesenberry CP Jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131:1017-1027.
25. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991; 17:969-976.
26. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994; 8:677-681.
27. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men. The Osaka Health Suvey. J Hypertens 2001; 19:1209-1215.
28. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474-480.
29. Nakanishi N, Okamato M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18:523-530.
30. Alper AB, ChenW, Yau L, Srinivasan S, Hamm LL, Berenson G. Childhood uric acid predicts adult blood pressure. The Bogalusa Heart Study. Hypertension 2005; 45:34-38.
31. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension 2005; 45:28-33.
32. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18:287-292.
33. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang DH, Finch J, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66:281-287.
34. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid induced C-reactive protein (CRP) expression: implication on cell proliferation and nitric oxide production in human vascular cells. J Am Soc Nephrol 2005; 16:3553- 3562.
35. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67:1739-1742.
36. Kang DH, Finch J, Nakagawa T, Karumanchi SA, Kanellis J, Granger J, et al. Uric acid, endothelial dysfunction and preeclampsia: searching for a pathogenetic link. J Hypertens 2004; 22:229-235.
37. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004; 94:932-935.
38. Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol 2000; 49:511.
39. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet derived growth factor A-chain expression. J Biol Chem 1991; 266:8604-8608.
40. Kang DH, Han L,Ouyang X, Kahn AM, Kanellis J, Li P, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005; 25:425-433.
41. Sulikowska B, Manitius J, Odrowaz-Sypniewska G, Lysiak-Szydlowska W, Rutkowski B. Uric acid excretion and dopamine-induced glomerular filtration response in patients with IgA glomerulonephritis. Am J Nephrol 2008; 28:391-396.
42. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004; 66:1465-1470.
43. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26:269-275.
44. Johnson RJ, Titte S, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25:3-8.45 Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodrguez-Iturbe B, Johnson RJ. A single pathway for the development of essential hypertension. Cardiol Rev 2003; 11:180-196.
45. quadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376:333-337.
46. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. ric acid and serum antioxidant capacity: a reaction to atherosclerosis Atherosclerosis 2000; 148:131-139.
47. Hink HU, Santanam M, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002; 22:1402-1408.
48. Johnson RJ, Rideout BA. Uric acid and diet - insights into the epidemic of cardiovascular disease. N Engl J Med 2004; 350:1071-1073.
49. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001; 87:1411-1414.
50. Kanellis J, Feig DI, Johnson RJ. Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease An old controversy renewed. Nephrology (Carlton) 2004; 9:394-399.
51. Short RA, Johnson RJ, Tuttle KR. Uric acid, microalbuminuria and cardiovascular events in high-risk patients. Am J Nephrol 2005; 25:36-44.
52. Kang DH, Nakagawa T, Feng L,Watanabe S, Han L, Mazzali M, et al. A rolefor uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-2897.
53. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005; 25:43-49.
54. Erdogan D, Gullu H, Caliskan M, Yildirim E, Bilgi M, Ulus T, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005; 59:1276-1278.
55. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346:913-923.
56. Rosolowsky ET, Ficociello LH, Maselli NJ, Niewczas MA, Binns AL, Roshan B, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008; 3:706-713.
57. Scolari F, Caridi G, Rampoldi L, Tardanico R, Izzi C, Pirulli D, et al. Uromodulin storage diseases: clinical aspects and mechanisms. Am J Kidney Dis 2004; 44:987-999.
58. Beck L. Requiem for gouty nephropathy. Kidney Int 1986; 30:280-287.
59. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41:1287-1293.
60. Kim YG, Huang XR, Suga S, Mazzali M, Tang D, Metz C, et al. nvolvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Mol Med 2000; 6:837-848.
61. Cirillo P, SatoW, Reungjui S, Heinig M, Gersch M, Sautin Y, et al. Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol 2006; 17:S165-S168.
62. Neilson EG. The fructose nation. J Am Soc Nephrol 2007; 18:2619-2622.
63. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005; 1:80-86.
64. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290:F625-F631.
65. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17:1466-1471.
66. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293:C584-C596.
67. Menè P, Festuccia F, Polci R, Pugliese F, Cinotti GA. Urate (UA) promotes Ca2 effiux and oxidative stress in cultured human mesangial cells (HMC). J Am Soc Nephrol 2001; 127:657.
68. Sanchez-Lozada LG, Tapia E, Jimenez A, Bautista P, Cristóbal M, Nepomuceno T, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol 2007; 292:F423-F429.
69. Bos MJ, Koudstaal PJ, Hofman A,Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006; 37:1503-1507.
70. Reungjui S, Roncal CA, MuW, Srinivas TR, Sirivongs D, Johnson RJ, et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. JAmSoc Nephrol 2007; 18:2624-2731.
71. Hawkins RG, Houston MC. Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States A hypothesis. Am J Hypertens 2005; 18:744-749.
72. Ono Y, Ono H, Frohlich ED. Hydrochlorothiazide exacerbates nitric oxide- blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996; 14:823-828.
73. JohnsonWD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 1991; 121:20-24.
74. Rashid MA, William-Olsson G. Influence of allopurinol on cardiac complications in open heart operations. Ann Thorac Surg 1991; 52:127-130.
75. Roncal CA, Mu W, Croker B, Reungjui S, Ouyang X, Tabah-Fisch I, et al. Effect of an elevated uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2007; 292:F116-F122.
76. Ahsan Ejaz A, MuW, Kang D-H, Roncal C, Sautin YY, Henderson G, et al. Could uric acid have a role in acute renal failure Clin J Am Soc Nephrol 2007; 2:16-21.
77. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44:642-650.
78. Cameron JS, Simmonds HA. Hereditary hyperuricemia and renal disease. Semin Nephrol 2005; 25:9-18.
79. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk of cardiovascular disease and mortality: the Framingham Heart Study. Ann Intern Med 1999; 31:7-13.
80. Short RA, Tuttle KR. Clinical evidence for the Influence of uric acid on hypertension, cardiovascular disease, and kidney disease: a statistical modeling perspective. Semin Nephrol 2005; 25:25-31.
81. Myllymäki J, Honkanen T, Syrjänen J, Helin H, Rantala I, Pasternack A, et al. Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 2005; 20:89-95.
82. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47:51-59.
83. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27:435-440.
84. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19:1204-1211.
85. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50:239-247.
86. Sánchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2008; 23:1179-1185.
87. Sánchez-Lozada LG, Tapia E, Bautista-Garcfía P, Soto V, Avila-Casado C, Vega-Campos IP, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol (Renal Physiol) 2008; 294:F710-F718.
88. Whelton A, MacDonald P, Lloyd E, Lademacher C. The long-term stability of renal function in hyperuricemic subjects with gout treated with febuxostat [abstract]. J Am Soc Nephrol 2007; 18:918.
89. Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson JA, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001; 71:900-905.
90. Mazzali M. Uric acid and transplantation. Semin Nephrol 2005; 25:50-55.
91. Sánchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M,Wessale JL, et al. Effect of Febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008; 108:69-78.